DiaMedica Initiates New Type 1 Diabetes Program

DiaMedica Inc., a Canadian biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders, announced the initiation of a type 1 diabetes program following the acquisition of Sanomune. The initiation of this program is based on encouraging preclinical results with DM-99, a naturally occurring protein that the company has previously shown to have clinical efficacy for type 2 diabetes. The initial results from this study, on animals, showed that DM-99 was able to reduce fasting blood glucose, an indication that new beta cells may be created or that existing beta cells are being protected.

The FDA has granted orphan drug designation for the DiaVacs's type 1 diabetes therapy, DV-0100. The therapy halt’s the body’s autoimmune reaction against the pancreatic islet cells which are responsible…

The Diabetes Media Foundation (DMF) is a 501(c)(3) tax-exempt nonprofit media organization, registered in New York and the IRS, under EIN #46-3338815. DMF is devoted to informing, educating, and generating community around, living a healthy life with diabetes.